- Home
- PHUN vs ADVM Comparison
PHUN vs ADVM Comparison
Compare PHUN & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- ADVM
- Stock Information
- Founded
- PHUN 2009
- ADVM 2006
- Country
- PHUN United States
- ADVM United States
- Employees
- PHUN N/A
- ADVM N/A
- Industry
- PHUN EDP Services
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHUN Technology
- ADVM Health Care
- Exchange
- PHUN Nasdaq
- ADVM Nasdaq
- Market Cap
- PHUN 58.3M
- ADVM 59.5M
- IPO Year
- PHUN N/A
- ADVM 2014
- Fundamental
- Price
- PHUN $2.91
- ADVM $2.29
- Analyst Decision
- PHUN Buy
- ADVM Strong Buy
- Analyst Count
- PHUN 2
- ADVM 5
- Target Price
- PHUN $7.50
- ADVM $26.40
- AVG Volume (30 Days)
- PHUN 192.4K
- ADVM 430.7K
- Earning Date
- PHUN 05-12-2025
- ADVM 05-14-2025
- Dividend Yield
- PHUN N/A
- ADVM N/A
- EPS Growth
- PHUN N/A
- ADVM N/A
- EPS
- PHUN N/A
- ADVM N/A
- Revenue
- PHUN $2,956,000.00
- ADVM $1,000,000.00
- Revenue This Year
- PHUN $10.47
- ADVM N/A
- Revenue Next Year
- PHUN $53.56
- ADVM $42.58
- P/E Ratio
- PHUN N/A
- ADVM N/A
- Revenue Growth
- PHUN N/A
- ADVM N/A
- 52 Week Low
- PHUN $2.22
- ADVM $1.78
- 52 Week High
- PHUN $14.60
- ADVM $10.14
- Technical
- Relative Strength Index (RSI)
- PHUN 46.42
- ADVM 40.10
- Support Level
- PHUN $2.86
- ADVM $2.15
- Resistance Level
- PHUN $3.18
- ADVM $2.33
- Average True Range (ATR)
- PHUN 0.14
- ADVM 0.23
- MACD
- PHUN -0.02
- ADVM 0.04
- Stochastic Oscillator
- PHUN 16.29
- ADVM 52.58
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.